Pharma BD Deal Intelligence
All three acquired brands were written down and Intal was discontinued outright — a small bolt-on that steadily bled value for eight years
Full analysis, sources & comparables →On December 30, 2002, King Pharmaceuticals licensed or acquired the rights to three branded pharmaceutical products from Aventis for the initial cash payment…
In 2001, about 20.3 million people (7.4% of the U.S. population) had asthma among all ages; between 2002 and 2018, current asthma prevalence ranged from a low…
Combination of two antibiotics used to treat infections caused by staphylococci and by vancomycin-resistant Enterococcus faecium; the two components work…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
December 30, 2002 acquisition of US rights to Intal (cromolyn), Tilade (nedocromil) and Synercid (quinupristin/dalfopristin) plus associated IP.
All three acquired brands were written down and Intal was discontinued outright — a small bolt-on that steadily bled value for eight years
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| King Pharmaceuticals Inc. / Aventis Pharmaceuticals (Intal/Tilade/Synercid rights) (this deal) | 2002 | $275M | 26 |
| King Pharmaceuticals Inc. / Jones Pharma Incorporated | 2000 | $3.4B | 54 |
| King Pharmaceuticals Inc. / Bristol-Myers Squibb (Corgard/Corzide/Delestrogen/Florinef rights) | 2001 | $285M | 51 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. | 2002 | $464M | 96 |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |